Dallas
214-456-5959
Fax: 214-456-5963
Park Cities
469-488-7000
Fax: 469-488-7001
Plano
469-303-2400
Fax: 469-303-2407
Request an Appointment with codes: Endocrinology
214-456-5959
Fax: 214-456-5963
469-488-7000
Fax: 469-488-7001
469-303-2400
Fax: 469-303-2407
Request an Appointment with codes: Endocrinology
Physical Effects of feminizing hormone can involve testosterone blocking medication alone, estrogen medication alone, or testosterone blocking medication along with estrogen.
Most physical changes associated with feminizing hormone therapy occur over the course of approximately two years. However, the amount of change and the exact timeline of effects can be highly variable. Factors that influence the amount and timeline of changes include inheritance (genetic influences passed down from biological parents), age, health status, lifestyle, and dosage (amount, frequency, route of administration).
TABLE 1: Effects and Expected Time Course of Feminizing Hormones (Print Friendly Version)
|
Expected |
Maximum |
Reversible? |
Comments |
Decreased Sex Drive |
1-3 mo |
1-2 yrs |
Yes |
|
Emotional Changes |
1-3 mo |
|
Yes |
|
Fertility |
Varies |
|
Likely, although prolonged use may decrease fertility |
|
Decreased Muscle Mass/Strength |
3-6 mo |
1-2 yrs |
Yes |
|
Breast Growth |
3-6 mo |
2-3 yrs |
No, although atrophy of breast tissue may occur |
|
Decreased Testicular Volume |
3-6 mo |
2-3 yrs |
Maybe |
|
Body Fat Redistribution |
3-6 mo |
2-5 yrs |
Yes |
|
Skin Softening |
3-6 mo |
|
Yes |
|
Face/Body Hair Changes |
6-12 mo |
|
No |
|
Inheritance (genetic influences passed down from biological parents), age, health status, lifestyle, and dosage (amount, frequency, route of administration) also impact the likelihood of experiencing negative side effects associated with feminizing hormone therapy.
Your healthcare provider will collect information regarding your history, as well as your biological family’s history, in order to provide more specific feedback regarding your risks prior to starting hormone therapy. Regular follow-up appointments are critical to monitoring your health and risk over time.
TABLE 2: Risks Associate with Masculinizing Hormones
Increased Risk Likely |
Venous thromboembolic disease (blood clots) |
|
Hypertriglyceridemia (elevation of triglycerides in blood) |
|
|
Weight gain |
|
|
Elevated liver enzymes |
|
|
Gallstones |
|
|
Increased Risk Likely with Additional Risk Factors Present |
Cardiovascular disease (heart disease) |
|
Possible Increased Risk |
Hypertension (high blood pressure) |
|
Hyperprolactinemia (elevated prolactin in blood) or prolactinoma (noncancerous pituitary gland tumor) |
|
|
Increased Risk Possible with Additional Risk Factors Present |
Type 2 diabetes |
|
No Increase Risk |
Breast cancer |
|
Information adapted from the World Professional Association for Transgender Health (WPATH) Standards of Care Version 7 and the Endocrine Society Clinical Practice Guideline for Endocrine Treatment of Transsexual Persons.
Information adapted from: